Naslov
Immune reactivity of renal transplant recipients receiving humanized anti-CD25 monoclonal antibodies during the early posttransplant period

Autori
Živčić-Ćosić, Stela ; Lisjak, Jasna ; Rački, Sanjin ; Trobonjača, Zlatko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Book of abstracts, 2011. Annual Meeting Of The Croatian Immunological Society / Polić, Bojan - Rijeka, 2011, 55-55

Skup
2011. Annual Meeting Of The Croatian Immunological Society

Mjesto i datum
Rabac, Hrvatska, 07.10.2011. - 09.10.2011

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
Immunosuppression; Renal graft transplantation; Proliferative response of lymphocytes; Anti-CD3; Cell cycle analysis; Flow Cytometry

Sažetak
Background: Immunosuppression should be applied according to the individual needs of renal allograft recipients. Methods of immune monitoring have been investigated to avoid complications of over- or underimmunosuppression. Methods: This prospective randomized trial included thirty renal allograft recipients in our center from 2006 until 2008. All patients received daclizumab in combination with mycophenolate mofetil, corticosteroids and a calcineurin inhibitor. Daclizumab was administered at a dosage of 1 mg/kg BW immediately before transplantation and every 15±1 days. During the first six weeks after transplantation the anti-CD3-stimulated proliferative response of peripheral blood T-lymphocytes (PBTL) was followed by cell cycle analysis. The proportion of PBTL in different phases of the cell cycle and the expression of interleukin-2 receptors (IL-2R) were analyzed by flow-cytometry. Results: As an effect of quadruple immunosuppressive therapy, including daclizumab, cell cycle analysis showed a step-wise decrease of the proliferative response of PBTL during the first six weeks after renal transplantation. A sudden drop in the proportion of IL-2R-positive cells was observed immediately after the first dose of daclizumab, and a significant antiproliferative effect on PBTL after the second dose two weeks after transplantation. In vitro, daclizumab inhibited dose-dependently, the anti-CD3 stimulated proliferation of PBTL of healthy blood donors. Conclusions: These results contribute to the knowledge about the effects of immunosuppressive drugs. Analysis of the immune reactivity of renal allograft recipients by cell-cycle analysis may represent a valuable tool for the immunological follow-up of renal transplant recipients and for the optimization of immunosuppressive treatment, in order to improve patient and graft survival.

Izvorni jezik
Hrvatski

Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti

POVEZANOST RADA